# MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study

> **NCT03403725** · PHASE1 · TERMINATED · sponsor: **Menarini Group** · enrollment: 28 (actual)

## Conditions studied

- Metastatic Solid Tumors
- Relapsed/Refractory Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** MEN1309

## Key facts

- **NCT ID:** NCT03403725
- **Lead sponsor:** Menarini Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-28
- **Primary completion:** 2019-10-22
- **Final completion:** 2020-01-08
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Terminated after achievement of MTD, without progressing to cohort expansion for Company decision.
- **Last updated:** 2021-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03403725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03403725, "MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03403725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*